EULAR/ACR 2019 SLE分类标准可预测疾病严重程度
该研究基于多伦多狼疮诊所867例SLE患者,评估EULAR/ACR 2019分类标准评分对诊断后5年内疾病严重程度的预测作用,并在SLICC队列验证。结果显示评分≥20分者疾病活动度更高、更易复发、缓解率更低且免疫抑制治疗需求更高,评分与调整平均SLEDAI 2000(AMS)相关(r=0.43,p≤0.001)。
要点
- EULAR/ACR评分≥20分提示SLE诊断后5年内疾病过程更活跃。
- 评分≥20分者AMS更高、更易复发、缓解率更低且免疫抑制需求更高。
- 评分与5年内AMS相关(r=0.43,p≤0.001),可提供预后信息。
核心结论
- EULAR/ACR评分≥20分是SLE疾病严重程度的指示指标。
- 评分≥20分者诊断后5年内疾病过程更活跃。
研究设计与样本
- 纳入多伦多狼疮诊所867例SLE患者(均为诊断后前12个月内),基于基线信息计算EULAR/ACR评分。
- 以诊断后5年内调整平均SLEDAI 2000(AMS)、复发、缓解和免疫抑制治疗为结局,SLICC登记队列为验证队列。
主要发现
- 基于ROC分析,以EULAR/ACR评分20分为阈值比较组间结局。
- 诊断后5年内,评分≥20分者AMS更高(p<0.001)且更可能经历复发(p<0.001)。
- 评分≥20分者达到缓解的概率更低且免疫抑制治疗需求更高,结果在SLICC验证队列中得到确认。
- 评分≥20分者诊断后5年内AMS为5.4% vs 3.1%(≥20 vs <20,p≤0.001)。
- 评分与同一时间框架内AMS相关(r=0.43,p≤0.001)。
关键数值与推荐
- EULAR/ACR评分≥20分作为指示疾病严重程度的阈值。
- 评分≥20分者诊断后5年内AMS为5.4% vs 3.1%(≥20 vs <20,p≤0.001)。
- 评分与AMS相关系数r=0.43(p≤0.001)。
临床怎么用
- 可将EULAR/ACR 2019分类标准评分≥20分用于识别诊断后5年内可能疾病过程更活跃、预后更差的SLE患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the ominosity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Systemic Lupus Erythematosus Classification Criteria by determining its predictive role for disease severity in the first 5 years following diagnosis. METHODS: 867 patients with systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic were included (all first 12 months after SLE diagnosis). The EULAR/ACR criteria score was calculated based on baseline information. To determine disease severity in the first 5 years after diagnosis, adjusted mean SLE Disease Activity Index 2000 (AMS), flares, remission and immunosuppressive treatment were used as outcomes. The Systemic Lupus International Collaborating Clinics (SLICC) registry comprised the validation cohort. RESULTS: Based on receiver operating characteristic analysis, a EULAR/ACR score of 20 was used as a threshold to compare outcomes between groups. In the first 5 years of disease course, patients with a score of ≥20 had higher AMS scores (p<0.001) and were more likely to ever experience a flare (p<0.001). These patients had lower probabilities of achieving remission and higher requirements for immunosuppressives. Results were confirmed in the SLICC validation cohort. Patients with a score of ≥20 had higher AMS during the first 5 years of disease (5.4 vs 3.1% and ≥20 vs <20 respectively, p≤0.001). The score correlated with AMS (r=0.43, p≤0.001) in the same time frame. CONCLUSION: A EULAR/ACR score of ≥20 is an indicator of ominosity in SLE. Patients with a score of ≥20 were characterised by a more active disease course throughout the first 5 years. These criteria provide prognostic information regarding disease severity in the first 5 years following diagnosis.
引用
- Whittall Garcia LP, Gladman DD, Urowitz M, et al. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. Ann Rheum Dis. 2021. PMID: 33452003. doi:10.1136/annrheumdis-2020-218670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。